Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Isabelle Bongiovanni-Delarozière"'
Autor:
Valentine Grumberg, Christos Chouaïd, Anne-Françoise Gaudin, Christophe Le Tourneau, Aurélien Marabelle, Isabelle Bongiovanni-Delarozière, François-Emery Cotté, Isabelle Borget
Publikováno v:
JCO Global Oncology, Vol , Iss 9 (2023)
PURPOSEIn 2020, the French National Authority for Health (Haute Autorité de Santé) published a methodologic guide called organizational impact (OI) cartography to define and structure assessment of the OI of health technologies. As immunotherapies
Externí odkaz:
https://doaj.org/article/59e0d1489d4f43e8bdb2660661d4727d
Publikováno v:
European Research in Telemedicine / La Recherche Européenne en Télémédecine
European Research in Telemedicine / La Recherche Européenne en Télémédecine, Elsevier Masson SAS, 2017, 6 (3-4), pp.117-135. ⟨10.1016/j.eurtel.2017.08.002⟩
European Research in Telemedicine / La Recherche Européenne en Télémédecine, Elsevier Masson SAS, 2017, 6 (3-4), pp.117-135. ⟨10.1016/j.eurtel.2017.08.002⟩
International audience; Context: Telemedicine is proposed as a useful tool to increase efficiency, improve access and the quality of care. The widespread use of telemedicine has created the need to evaluate its efficiency. This implies that we need u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a2ff3a9cb313d78c491934bf2c814d7
https://hal.archives-ouvertes.fr/hal-01661660
https://hal.archives-ouvertes.fr/hal-01661660
Autor:
Olivier Scemama, Catherine Rumeau-Pichon, Isabelle Bongiovanni-Delarozière, Anne-Line Couillerot-Peyrondet
Publikováno v:
Revue française des affaires sociales. 1:113
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77aaf34373dee279746f620366cb0c52
https://doi.org/10.3917/rfas.193.0113
https://doi.org/10.3917/rfas.193.0113
Autor:
Yoël Sainsaulieu, Anne-Line Couillerot-Peyrondet, Cléa Sambuc, Isabelle Bongiovanni-Delarozière, Cécile Couchoud
Publikováno v:
The European journal of health economics : HEPAC : health economics in prevention and care. 18(4)
In the current pressured economic context, and to continue to treat the growing number of patients with high-quality standards, the first step is to have a better understanding of the costs related to end-stage renal disease (ESRD) treatment accordin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33bed2652fa5001e50f9e97ca8472ebe
https://pubmed.ncbi.nlm.nih.gov/27146313
https://pubmed.ncbi.nlm.nih.gov/27146313